Abstract

Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3

Author(s): Zur Eyal

Issue: Sep/Oct 2019 - Volume 23, Number 5

Page(s): 366-375

Download in electronic PDF format for $75

Abstract

Cutaneous leishmaniasis is the most common form of leishmaniasis with global incidence of about 1.5 million cases annually. The disease is endemic in Israel and caused by two types, leishmania major and leishmania tropica. The two types of cutaneous leishmaniasis in Israel are not life threatening, but the multiple skin lesions developed from the contaminated sandfly bites cause significant damage to the quality of life for a few months in patients with leishmania major and sometimes for more than a year in patients with leishmania tropica. Topical treatment for this localized skin disease is very attractive although only one medication is registered in Israel (15% paromomycin +12% methylbenzethonium chloride ointment) for the topical treatment of leishmania major. Two significant disadvantages characterize this topical medication, 1) relatively low efficacy and 2) significant irritation and pain. This article represents part 3 of a 3-part article on the topic of cutaneous leishmaniasis. Part 1 discussed the treatment option of amphotericin-B liposomal gel, part 2 discussed the treatment option of paromomycin sulfate liposomal gel, and this final part (3) discusses the treatment option of photodynamic therapy.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Sep/Oct 2019 Pg. 366-375	Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3 Author(s): Zur Eyal
Jul/Aug 2019 Pg. 288-293	Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 2 Author(s): Zur Eyal
May/Jun 2019 Pg. 200-207	Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 1 Author(s): Zur Eyal
Jul/Aug 2003 Pg. 266-270	Sensitization Therapy for Warts Author(s): Kuntz Rachael
Jul/Aug 2004 Pg. 269-274	Current Topical Treatments in Wound Healing - Part 1 Author(s): Helmke Christopher D
Sep/Oct 2015 Pg. 357-365	Novel Approaches to Topical Psoriasis Therapy Author(s): Koyama Gregory, Liu Jenny, Scaffidi Alyse, Khazraee Maryam, Epstein Benjamin
May/Jun 2009 Pg. 262-263	PostScription: Compounding in Israel Author(s): Zur Eyal
Nov/Dec 2018 Pg. 446-454	Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications Author(s): Zur Eyal
Jul/Aug 2003 Pg. 288-291	Basics of Compounding for Raynaud's Disease Author(s): Glasnapp Andrew
Jul/Aug 1999 Pg. 309-310	Acidifying Agents, Featured Excipient: Author(s): Allen Loyd V Jr
Nov/Dec 2011 Pg. 458-463	Infantile Hemangiomas, Part 2: Topical Treatment with Beta Blockers Author(s): Zur Eyal
Jan/Feb 2019 Pg. 23-31	Topical Treatment of Primary Focal Hyperhidrosis, Part 1 Author(s): Zur Eyal
Nov/Dec 2018 Pg. 516-526	Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4 Author(s): Polonini Hudson, da Silva Sharlene Loures, Brandão Marcos Antônio Fernandes, Bauters Tiene, De Moerloose Barbara, Ferreira Anderson de Oliveira
Sep/Oct 2004 Pg. 354-357	Current Topical Treatments in Wound Healing - Part 2 Author(s): Helmke Christopher D
Mar/Apr 2019 Pg. 94-104	Topical Treatment of Primary Focal Hyperhidrosis, Part 2 Author(s): Zur Eyal
Nov/Dec 2022 Pg. 480-488	A Compendium of Compounding Agents and Formulations, Part 6: Additional Preparations for Refractory Dermal-wound Healing Author(s): Riepl Mike
May/Jun 2003 Pg. 176-178	Case Report: Topical Gel for the Treatment of a Refractory Leg Ulcer Author(s): Israel Alan
Sep/Oct 2022 Pg. 423	Ascorbic acid 5% Topical Microemulsion Author(s): Allen Loyd V Jr
Sep/Oct 2015 Pg. 410	Trichloroacetic Acid 20%, Salicylic Acid 20%, Lactic Acid 10% in Flexible Collodion Author(s): Allen Loyd V Jr
May/Jun 2015 Pg. 243	Lidocaine Hydrochloride 2% Viscous Oral Topical Solution Author(s): Allen Loyd V Jr